Development and validation of the Dermatomyositis Skin Severity Index

British Journal of Dermatology

Volumn 158, Issue 2, 2008, Pages 345-350

  Carroll, C L ^a   Lang, W ^a   Snively, B ^a   Feldman, S R ^a   Callen, J ^b   Jorizzo, J L ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

Connective tissue disease; Dermatology Life Quality Index; Dermatomyositis; Quality of life; Skindex 16

Indexed keywords

ADULT; ARTICLE; CONSTRUCT VALIDITY; CONTENT VALIDITY; CORRELATION ANALYSIS; DERMATOMYOSITIS; DERMATOMYOSITIS SKIN SEVERITY INDEX; FEMALE; HUMAN; INTERRATER RELIABILITY; MAJOR CLINICAL STUDY; MALE; POIKILODERMA; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RATING SCALE; REPRODUCIBILITY; SKIN DISEASE; SKIN ULCER; TEST RETEST RELIABILITY; VALIDATION PROCESS;

EID: 38349187559     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08342.x     Document Type: Article

References (18)

1. Adams EM, Plotz PH. The treatment of myositis. How to approach resistant disease. Rheum Dis Clin North Am 1995 21 : 179 202.
2. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975 292 : 344 7.
3. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975 292 : 403 7.
4. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991 325 : 1487 98.
5. Ghate J, Katsambas A, Augerinou G et al. Review article: a therapeutic update on dermatomyositis/polymyositis. Int J Dermatol 2000 39 : 81 7.
6. Jorizzo JL. Dermatomyositis: practical aspects. Arch Dermatol 2002 138 : 114 16.
7. Hanissian AS, Masi AT, Pitner SE et al. Polymyositis and dermatomyositis in children: an epidemiologic and clinical comparative analysis. J Rheumatol 1982 9 : 390 4.
8. Cosnes A, Amaudric F, Gherardi R et al. Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids. Arch Dermatol 1995 131 : 1381 5.
9. Dawkins MA, Jorizzo JL, Walker FO et al. Dermatomyositis: a dermatology-based case series. J Am Acad Dermatol 1998 38 : 397 404.
10. Isenberg DA, Allen E, Farewell V et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004 43 : 49 54.
11. Lovell DJ, Lindsley CB, Rennebohm RM et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum 1999 42 : 2213 19.
12. Rider LG. Assessment of disease activity and its sequelae in children and adults with myositis. Curr Opin Rheumatol 1996 8 : 495 506.
13. Ruperto N, Ravelli A, Murray KJ et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford) 2003 42 : 1452 9.
14. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978 157 : 238 44.
15. Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007 143 : 763 7.
16. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 19 : 210 16.
17. Chren MM, Lasek RJ, Sahay AP et al. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 2001 5 : 105 10.
18. Faust HB, Gonin R, Chuang TY et al. Reliability testing of the Dermatology Index of Disease Severity (DIDS). An index for staging the severity of cutaneous inflammatory disease. Arch Dermatol 1997 133 : 1443 8.